Equity Overview
Price & Market Data
Price: $4.19
Daily Change: -$0.21 / 5.01%
Range: $4.10 - $4.46
Market Cap: $17,831,982
Volume: 66,890
Performance Metrics
1 Week: -3.67%
1 Month: -1.18%
3 Months: 16.99%
6 Months: -3.00%
1 Year: -50.70%
YTD: -14.81%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.